Skip to main content

Clinical trial ELUCIDATE

A Phase 1/2 open-label multicenter study to assess the safety, pharmacokinetics, and anti-tumor activity of GTAEXS617 in patients with advanced solid tumors.

Cancers
Organ Multiple
Trial status Trial open for recruitment
Investigator
Trial type
Interventional with experimental drug
Phase Trial phase 1/2
Academic trial Non
Sponsor Exscientia AI Limited
EudraCT Identifier 2023-508227-13-00
ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT05985655
Last update